Company Active LTD

Company profile

Trueinvivo Limited

TRUEinvivo The micro silica thermoluminescent radiation detector company!

Trueinvivo Limited is a UK company with status active founded in 2014 based in South East England.

CRN
09337185
Founded
2014
Age
11

Overview

Legal name
TRUEINVIVO LIMITED
Region
South East England
Registered address
THE WHITE HOUSE
2 MEADROW
GODALMING
SURREY
GU7 3HN
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

8 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

16 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

02 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

25 Feb
2025

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQ1NjM0NzU3M2FkaXF6a2N4

Published 25 Feb 2025 14:56

24 Sep
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQzNzAwOTA3OGFkaXF6a2N4

Published 24 Sep 2024 01:01

12 Sep
2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQzNTM4NDExN2FkaXF6a2N4

Published 12 Sep 2024 09:21

02 Dec
2014

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2015
Funded years
2015, 2017, 2019, 2020
Age at first award
0 years

Projects

2020 Collaborative R&D Lead participant

Pre-clinical testing of glass bead dosimeters and related dose comparison software to enable safer hypofractionation to sustainably and quickly clear the radiotherapy treatment backlog caused by COVID-19.

1 Oct 2020 to 30 Jun 2021

Awarded
£169,610
Total cost £226,146

**The extensive backlog in cancer treatment caused by COVID-19 is well documented. One solution in radiotherapy is to reduce the number of treatment sessions (called fractions) that a patient needs by increasing the strength of the delivered doses in each one, a technique called hypofractionation. For instance, a typical prostate treatment of 30 or 35 fra...

2019 Collaborative R&D Lead participant

Development of a 3D cavity dosimeter and image analysis software for in-body invivo dose measurement of organs at risk to make radiotherapy safer for patients and more efficient for clinicians

1 Jan 2019 to 31 Mar 2021

Awarded
£189,537
Total cost £270,767

It is currently estimated that 1 in 2 people will have cancer and of these around 40% will receive radiotherapy treatment (cancerresearchuk.org). Radiotherapy involves using ionising radiation to treat tumours and has been a key element of cancer treatment for decades. However 10-25% of radiotherapy patients are damaged or failed by their treatment often ...

2017 Collaborative R&D Lead participant

TrueInvivo solution to improve cancer servival rate

1 Jan 2017 to 31 Dec 2018

Awarded
£50,000
Total cost £50,000

Current radiotherapy treatments for cancer use beams of radiation to kill the actual tumour cells and try to miss the healthy surrounding cells and organs. However, the beams are invisible and very often damage does occur. Many radiotherapy centres use a pattern of tiny beams to closely match the shape of the target tumour but it is hugely difficult to kn...

2015 Vouchers Lead participant

TrueInvivo 2

1 Aug 2015 to 31 Jan 2016

Awarded
£5,000
Total cost £5,000

Awaiting Public Project Summary

Product types

Collaborative R&D Vouchers